Glucagon receptor modulators

US8859591B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Gary Erik Aspnes · Biberach an der Riß, DE
• Mary Theresa Didiuk · Madison, US
• Kevin James Filipski · Reading, US
• Angel Guzman-Perez · Belmont, US
• Esther Cheng Yin Lee · Brookline, US
• Jeffrey Allen Pfefferkorn · Mystic, US
• Benjamin Dawson Stevens · Cambridge, US
• Meihua Mike Tu · Mystic, US

Key dates

• Filing date: Jul 3, 2013
• Grant date: Oct 14, 2014
• Expiry date: Jul 3, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of Formula (I)or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.